Unfortunately, this approach was not effective as monotherapy, although it showed partial response in combination with anti-PD-1 in patients with advanced solid tumors or lymphomas.55 Another STING agonist (ADU-S100, Aduro Biotech), in combination with anti-PD1 or anti-CTLA4, is in multiple clinical trials including head and neck, advanced/metastatic solid tumors or lymphomas (clinicaltrials.gov identifier: NCT03937141, 02675439, 03172936). Here, STING1 is linked to lymphoma.